Kunming Medicine Group

KPC Pharmaceuticals, formerly known as Kunming Medicine Group, is a prominent Chinese pharmaceutical enterprise specializing in the development and manufacture of natural plant-based medicines. Founded in 1951 and headquartered in Yunnan, the company is a global leader in artemisinin-based antimalarial production and a pioneer in the industrialization of Panax notoginseng for cardiovascular health. KPC maintains a robust portfolio centered on Traditional Chinese Medicine (TCM) modernization, chemical drugs, and healthcare products. In 2022, the company became a subsidiary of China Resources Pharmaceutical Group, facilitating a strategic integration into the broader national healthcare infrastructure. KPC is recognized for its high-quality manufacturing standards and its significant contributions to global health through its supply of essential antimalarial treatments to international organizations.